Results 241 to 250 of about 6,251,756 (328)

Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study (COVER Study)

open access: yesAllergy, EarlyView.
This prospective multicenter study corroborates the efficacy of AIT with the native HDM allergen extract in Chinese AR patients with diverse HDM sensitization patterns. HDM sensitization pattern affects the efficacy of AIT, with patients sensitized to both major and minor allergens of HDM showing improved outcomes with HDM SCIT.
Qingxiu Xu   +14 more
wiley   +1 more source

Active Surveillance for Myocarditis and Pericarditis in Canadian Children from 2021 to 2022: A Canadian Immunization Monitoring Program ACTive Study

open access: bronze
Karina A. Top   +24 more
openalex   +2 more sources

The Therapeutic Potential of Farm Dust Extracts in a Mouse Model of Eosinophilic Inflammation

open access: yesAllergy, EarlyView.
Farm dust extract (FDE) treatment reduces airway eosinophilia, mucus overproduction, and MHC‐II expression on DCs, limiting antigen presentation and Th2 inflammation. It increases PD‐L1 on DCs, promoting T cell deactivation. Additionally, FDE enhances Tregs and upregulates CTLA‐4, reinforcing suppression.
Rabia Ülkü Korkmaz   +16 more
wiley   +1 more source

First Field Test of the Novel Integration Mapping Tool for COVID-19 Vaccination Integration into National Immunization Programs and Primary Healthcare - A Case Study from Cote d'Ivoire

open access: yes, 2023
Amani A   +13 more
europepmc   +1 more source

Major Cat Allergen Fel d 4: Structure and Identification of a Cross‐Reactive IgE‐Epitope‐Containing Area

open access: yesAllergy, EarlyView.
This study reports the three‐dimensional structure of an important cat allergen, Fel d 4, that shares high homology with Equ c 1 (i.e., major horse allergen) and Can f 6 (i.e., dog allergen). The C‐terminal region of the Fel d 4 contains a major IgE‐reactive epitope.
Nikolina Todorović   +14 more
wiley   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy